

Comparison of Claims Between U.S. Patent Nos. 6,774,122; 7,456,160; 8,329,680; 8,466,139				
	6,774,122 <i>Independent Claims 1 and 5</i>	7,456,160 <i>Independent Claims 1 and 2</i>	8,329,680 <i>Independent Claims 1 and 9</i>	8,466,139 <i>Independent Claim 1 and 11</i>
Treatment	A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract			
Injection Type	Intramuscularly to a human			
Fulvestrant	>45 mgml ⁻¹ of fulvestrant (<i>claim 5</i>)	>45 mgml ⁻¹ of fulvestrant (<i>claim 2</i>)	about 50 mgml ⁻¹ fulvestrant	about 50 mgml ⁻¹ fulvestrant
Ethanol	10% w/v	10-30% w/v combined	about 10% w/v	17-23% w/v combined
Benzyl Alcohol	10% w/v		about 10% w/v	
Benzyl Benzoate	15% w/v	10-25% w/v	about 15% w/v	12-18% w/v
Castor Oil	a sufficient amount ¹			
PK Result	whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml ⁻¹ is attained for at least 2 weeks after injection (<i>claim 1 only</i>)	whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml ⁻¹ is attained for at least 2 weeks after injection (<i>claim 1 only</i>)	wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml ⁻¹ for at least four weeks	wherein the method achieves a blood plasma fulvestrant concentration of at least 2.5 ngml ⁻¹ for at least two weeks

¹ Omitted from U.S. Patent No. 8,329,680, claim 9.

Dependent Claims				
	6,774,122 <i>Independent Claims 1 and 5</i>	7,456,160 <i>Independent Claims 1 and 2</i>	8,329,680 <i>Independent Claims 1 and 9</i>	8,466,139 <i>Independent Claim 1 and 11</i>
Breast Cancer	2, 9 3-4 Claim 3: $\geq 2.5 \text{ ngml}^{-1}$ for ≥ 4 weeks Claim 4: $\geq 2.5 \text{ ngml}^{-1}$ for $\geq 2-5$ wks.	12 5-9 Claim 5: $\geq 2.5 \text{ ngml}^{-1}$ for ≥ 3 weeks Claim 6: $\geq 2.5 \text{ ngml}^{-1}$ for ≥ 4 weeks Claim 7: $\geq 3 \text{ ngml}^{-1}$ for ≥ 2 weeks Claim 8: $\geq 8.5 \text{ ngml}^{-1}$ for ≥ 2 weeks Claim 9: $\geq 8.5 \text{ ngml}^{-1}$ for ≥ 4 weeks	3, 6, 11, 14 2, 10 Claim 2: $\geq 8.5 \text{ ngml}^{-1}$ for ≥ 4 wks. Claim 10: $\geq 2.5 \text{ ngml}^{-1}$ for ≥ 4 wks.	5, 10, 15, 20 4, 6, 10, 14, 16, 20 Claims 4, 14: $\geq 8.5 \text{ ngml}^{-1}$ for ≥ 2 weeks Claims 6, 10, 16, 20: $\geq 2.5 \text{ ngml}^{-1}$ for ≥ 4 weeks
Divided Dose			17-20	9, 19
Once Monthly			5, 8, 13, 16	8, 18
Limiting Injection Volume	6-8 Claims 6, 7: $\leq 6 \text{ ml}$ Claim 8: 5-5.25 ml	10-11 Claims 10, 11: $\leq 6 \text{ ml}$	4, 7, 12, 15 Claims 4, 7, 12, 15: 5 ml	7, 17 Claims 7, 17: 5 ml
Limiting Conc. & Dose	6-8 Claims 5, 6: $\geq 45 \text{ mgml}^{-1}$ Claim 7: $\geq 250 \text{ mg}$ Claim 8: 250mg	10-11 Claim 2, 10: $\geq 45 \text{ mgml}^{-1}$ Claim 11: $\geq 250 \text{ mg}$		
Further Narrowing Excipient %		3-4 Claim 3: 15-25% w/v ethanol & benzyl alcohol, 12-20% w/v benzyl benzoate Claim 4: 8.5-11.5% w/v ethanol, 8.5-11.5% w/v benzyl alcohol, 12-18% w/v benzyl benzoate		2-3, 12-13 Claims 2, 12: 19-21% w/v ethanol & benzyl alcohol, 14-16% w/v benzyl benzoate Claims 3, 13: about 10% w/v ethanol, about 10% w/v benzyl alcohol, about 15% w/v benzyl benzoate